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Background and objective: There are no recent data on the prevalence of drug-resistant tuberculosis (DR TB)
in Cambodia. We aim to describe TB drug resistance amongst adults with pulmonary and extra-pulmonary
TB and human immunodeficiency virus (HIV) co-infection in a national referral hospital in Phnom Penh,
Cambodia.
Design: Between 22 November 2007 and 30 November 2009, clinical specimens from HIV-infected patients
suspected of having TB underwent routine microscopy, Mycobacterium tuberculosis culture, and drug
susceptibility testing. Laboratory and clinical data were collected for patients with positive M. tuberculosis
cultures.
Results: M. tuberculosis was cultured from 236 HIV-infected patients. Resistance to any first-line TB drug
occurred in 34.7% of patients; 8.1% had multidrug resistant tuberculosis (MDR TB). The proportion of
MDR TB amongst new patients and previously treated patients was 3.7 and 28.9%, respectively (pB0.001).
The diagnosis of MDR TB was made after death in 15.8% of patients; in total 26.3% of patients with MDR
TB died. The diagnosis of TB was established by culture of extra-pulmonary specimens in 23.6% of cases.
Conclusions: There is significant resistance to first-line TB drugs amongst new and previously treated TB
HIV co-infected patients in Phnom Penh. These data suggest that the prevalence of DR TB in Cambodia may
be higher than previously recognised, particularly amongst HIV-infected patients. Additional prevalence
studies are needed. This study also illustrates the feasibility and utility of analysis of non-respiratory
specimens in the diagnosis of TB, even in low-resource settings, and suggests that extra-pulmonary specimens
should be included in TB diagnostic algorithms.
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T
uberculosis (TB) has re-emerged as one of the
most significant infectious diseases of modern
times, after more than a century of declining inci-
dence and mortality (1). TB was responsible for an esti-
mated 1.3 million deaths worldwide in 2012 (2). The
emergence of human immunodeficiency virus (HIV) in-
fection has driven the resurgence of TB, particularly in
resource-limited countries (2, 3), where the ability to
diagnose, treat, and control either disease may be limited.
These problems are compounded by the emergence of
drug-resistant tuberculosis (DR TB), the extent of which
is often unknown in a population and undiagnosed in in-
dividuals (4). Of particular concern is multidrug-resistant
tuberculosis (MDR TB), defined as resistance to at least
rifampicin and isoniazid, which requires prolonged,
poorly tolerated, and expensive treatment.
The World Health Organization (WHO) defines
Cambodia as a country with a high burden of TB (2). In
2012, the estimated prevalence of TB was 764 per 100,000
population (range 645892 per 100,000). HIV co-infection
was sought in 80% of notified cases of TB and found in 4%
(2). The last Cambodian national drug resistance survey is
more than 10 years old and reported no cases of MDR TB
amongst new cases and a prevalence of 3.6% (95% CI 1.0
9.0) amongst previously treated cases (5). The WHO esti-
mated that MDR TB comprised 1.4% of new cases and
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11% of previously treated cases of TB in Cambodia in
2012. This equated to 386 expected new and previously
treated cases of MDR pulmonary TB, although only 102
were notified that year (2, 4).
There are few specific data on the prevalence of DR TB
in HIV-infected patients in Cambodia. The CAMELIA
study (6), a large randomised clinical trial investigating the
mortality impact of early antiretroviral therapy (ART) in
TBHIV co-infected patients, enrolled HIV-infected
adults with CD4 count B200/mm3 and a first episode of
pulmonary or extra-pulmonary TB. In this study, 13
patients had MDR TB (13/645, 2%) and 73 patients had
isoniazid resistance (73/645, 11%). A laboratory-based
study conducted in Phnom Penh, Cambodia, found an
MDR TB prevalence of 5.5% in 98 samples from HIV-
infected patients, but case definitions were not assigned to
the drug resistance patterns (7). A 2002 survey of 441 HIV-
infected patients in Phnom Penh identified culture-positive
pulmonary TB in 9%; isoniazid resistance was identified in
15%, and no MDR TB was found (8).
In this paper, we report the proportion of drug-resistant
pulmonary and extra-pulmonary TB in a cohort of HIV-
infected patients at a national referral hospital in Phnom
Penh.
Methods
Study design and population
This is a retrospective observational cohort study of
consecutive Mycobacterium tuberculosis culture-positive
TBHIV co-infected inpatients and outpatients managed
by the Infectious Diseases Unit of Preah Bat Norodom
Sihanouk Hospital (Khmer-Soviet Friendship Hospital)
over 2 years (November 2007 to November 2009). Preah
Bat Norodom Sihanouk Hospital is a large public hospital
in Phnom Penh providing healthcare to a generally impov-
erished population; 58% of the cohort earned less than
200,000 riels (around USD50 per month) [MSF internal
report, Phnom Penh]. Me´decins Sans Frontie`res (MSF)
supported a TBHIV programme from 2005 until 2010
and an MDR TBHIV programme from 2007 until 2009.
Patients enrolled in the HIV cohort were referred from a
variety of sources (Table 1) [MSF internal report, Phnom
Penh 2007]. After February 2009, in an attempt to limit
growth of the cohort prior to integration with the
Cambodian National HIV programme, the 233 new HIV
patients included in the cohort were mostly inpatient
referrals who were eligible for anti-retroviral therapy
(ART) [MSF internal report, Phnom Penh 2009].
Most patients were from Phnom Penh (61.6%); 26.4%
were from the surrounding provinces of Kandal, Kampong
Speu, Prey Veng, Kampong Cham, and Kampong Chhnang.
The remaining 12% were from distant provinces [MSF
internal report, Phnom Penh 2008].
From 22 November 2007, culture for M. tuberculosis
and drug susceptibility testing (DST) was routinely
performed on specimens from HIV-infected patients aged
15 years and above, suspected of having either pulmonary
or extra-pulmonary TB. Patients were suspected of having
pulmonary TB if they had had a cough for more than
2 weeks (9). In addition, patients with unexplained fever or
weight loss were suspected of having pulmonary and/or
extra-pulmonary TB, as were patients with specific signs
or symptoms (e.g. lymphadenopathy) consistent with
extra-pulmonary TB.
Patients diagnosed with TB were assigned case defini-
tions according to standard WHO definitions (10). WHO
definitions describing treatment history were also applied:
‘new cases’ or previously treated cases (either ‘relapsed’,
‘failed’, or ‘interrupted treatment’) (10). Patients who did
not fit the above definitions were described as ‘other’ cases.
Descriptions of M. tuberculosis drug resistance were also
assigned according to WHO definitions (11).
Laboratory procedures
The decision to test a patient suspected of having TB was
made according to MSF protocols for the diagnosis of
pulmonary TB in HIV-infected patients, based on the
symptoms listed above (9); in cases of extra-pulmonary TB
Table 1. Source of referral of new patients included in HIV cohort (2007)
Source of referral Number of patients, n824 (%) Inpatients (%) Outpatients (%)
VCT centre 207 (25.1) 30 (14.4) 177 (85.6)
Respiratory department 141 (17) 17 (12.1) 124 (87.9)
Self-referral via emergency department 174 (21.1) 164 (94.3) 10 (5.7)
Other hospital departments 8 (1.0) 8 0
Family/contact of existing patient 110 (13.3) 1 (0.9) 109 (99.1)
Private doctor 46 (5.6) 15 (32.6) 31 (67.4)
Transfer from another HIV cohort 95 (11.5) 50 (52.6) 45 (47.4)
Prisoner 18 (2.2) 2 16
Other 25 (3.0) 4 21
VCT: Voluntary Counselling and Testing centre.
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or where there was a strong suspicion of pulmonary TB not
fulfilling the criteria of protocols, the treating clinician’s
discretion and other published MSF guidance was also
used to inform testing decisions (9). Where pulmonary
TB was suspected, two sputum samples were collected and
sent to the Pasteur Institute in Phnom Penh for culture and
DST. Gastric lavage was used if the patient could not
produce sputum, and bronchoalveolar lavage (BAL)
could also be performed. In the case of suspected extra-
pulmonary TB, specimens from other sites (e.g. aspirated
pus) were sent for microscopy and culture.
Smear microscopy was performed using a conventio-
nal fluorescence microscopy after specimen concentra-
tion using high-speed centrifugation. M. tuberculosis was
cultured on LowensteinJensen solid media and liquid
MGIT (mycobacterial growth indicator tube) media, using
the BD MGIT reading manual method prior to May 2009
and the MGIT Bactec 960 method thereafter. DST was
performed for any positive M. tuberculosis isolate against
first-line drugs (rifampicin, isoniazid, ethambutol, and
streptomycin), using MGIT. Patients with positive non-
tuberculous mycobacterial cultures or mixed cultures were
excluded from this analysis.
Data collection and statistical analysis
The authors (GW, SB, and TD), who were also treating
clinicians over the study period, collected clinical informa-
tion from the hospital and laboratory records of patients
with positive M. tuberculosis cultures. Data initially
collected included gender, geographic origin, and source
of entry in to the cohort, site of TB, past TB treatment
history, type of clinical specimen, smear status, and drug
susceptibility results. Anonymised data were entered into
an Excel spreadsheet using the reference number assigned
to each patient on enrolment in to the HIV cohort. At a
later date, additional data were collected by one of the
authors (GW) from the MSF HIV programme database
(FUCHIA) using the anonymised reference numbers. No
identifiable patient details were available from FUCHIA.
These data included age, CD4 count, other opportunistic
infection, start date of antiretroviral treatment and TB
treatment, and date of entry in to the HIV cohort. In some
instances, not all additional data were complete, and
patients’ hospital records were no longer available for
perusal.
This paper is descriptive and reports data used for
clinical decision making, reflecting a routine standard of
care in this programme. The data were collected by
clinicians involved in patients’ care and all personal data
were immediately anonymised before further analysis or
later data collection occurred. No intervention occurred
based on the anonymised data. Therefore, ethics com-
mittee approval was not sought and patients did not sign
an informed consent.
The characteristics of patients and specimens from
culture-confirmed TB patients are presented. The pro-
portions of each type of drug resistance were calculated
for new and previously treated cases, and were compared
using Chi-squared tests (Stata Data Analysis and Statis-
tical Software, Version 12.0).
Results
Between 1 November 2007 and 30 November 2009, 658
cases of TB were reported in the programme’s cohort of
3,612 HIV-infected adult patients (18.2%) who received
inpatient and outpatient care over the study period. M.
tuberculosis infection was confirmed by culture in 236
patients (236/658 cases, 35.9%). Case definitions of the 236
culture-positive patients were as follows: 187 new cases
(187/236, 79.2%) and 38 previously treated cases (38/236,
16.1%): 26 relapsed (26/38, 68.4%), 6 who had failed
treatment (6/38, 15.8%) and 6 who had interrupted pre-
vious TB treatment (6/38, 15.8%). The remainder with
either transferred in from another cohort or ‘other’ case
definitions (Fig. 1).
Table 2 describes characteristics of the patients with
culture-positive pulmonary and extra-pulmonary TB. The
majority of patients were male (152/236 patients, 64.4%)
with a low median CD4 count (52 cells/mm3); 12.2% also
had other opportunistic infections at TB diagnosis. More
than half of patients had extra-pulmonary involvement
(130/236 patients, 55.1%), indicating widespread disease.
Only 61.6% were on ART at the time of TB diagnosis,
despite the low median CD4 count. Of those not on ART
at the time of TB diagnosis (63/164 patients, 38.4%), 50
patients (79.4%) recorded a date of enrolment in to the
HIV cohort within 1 month before starting TB treatment,
Fig. 1. TB cases amongst HIV-infected patients.
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indicating that the diagnosis of TB was the precipitant for
enrolment in to the HIV cohort, and possibly the reason
for the diagnosis of HIV. Of those on ART, TB was
diagnosed within 60 days after starting ART in 48.5% of
those patients, possibly indicating that TB was a mani-
festation of an immune reconstitution inflammatory
syndrome (IRIS), or that ART was started concurrently
with, or soon after, TB treatment.
One-third of the TBHIV cohort came from outside
Phnom Penh and patients were referred by a variety of
services, both inpatient from the emergency department
and other hospital departments (60.2%), and outpatient
(18.6%), giving a mix of acutely unwell and ambulatory
patients. After February 2009, patient enrolment into the
HIV cohort (but not the HIVTB cohort) was limited,
and most of the 233 new HIV patients were referred from
inpatient services. After February 2009, 43 patients were
included in the TBHIV cohort; before February 2009,
193 patients were included. There was no statistically
significant difference in the proportions of DR TB seen in
patients enrolled before and after February 2009.
Table 3 shows the proportion of drug resistance accor-
ding to case definition. In total, 82 patients (82/236,
34.7%) had infection with an M. tuberculosis isolate
exhibiting some form of drug resistance. MDR TB was
identified in 8.1% (19/236 patients). Information on treat-
ment was available for 14/19 patients (73.7%) with MDR
TB. Three patients (3/19, 15.8%) were diagnosed with
MDR TB after death and two others died while on MDR
TB treatment (5/19 total deaths, 26.3%). One declined
treatment. Three received empiric MDR TB treatment
before culture results were available. Seven received MDR
TB treatment after culture results; the median delay in
treatment initiation was 14 days (range 6151 days).
The proportion of MDR TB was higher amongst
previously treated cases than new cases [11/38 previously
treated patients (28.9%) vs. 7/187 new patients (3.7%);
pB0.001], as was the proportion of rifampicin mono-
resistance and rifampicin with streptomycin resistance [7/
38 patients (18.4%) vs. 3/187 patients (1.6%); pB0.001]. Of
the 19 patients with MDR TB, seven (7/19, 36.8%) had not
previously received TB treatment.
Patients with sputum-smear negative pulmonary TB
were more likely to culture a fully susceptible organism
than those with smear-positive pulmonary TB [113/153
patients (73.9%) vs. 42/47 patients (89.4%); p0.028],
and those with pulmonary TB were more likely to cul-
ture a fully susceptible organism than those with extra-
pulmonary TB [155/204 patients (76.0%) vs. 16/28 patients
(57.1%); p0.041]. Otherwise there was no significant
difference between site of TB, smear status, and the
identification of resistant organisms in culture.
Table 4 shows the proportion of drug-resistant TB
according to HIV demographics and HIV disease profiles.
There was no statistically significant difference in the
proportion of susceptible or drug-resistant TB between
men and women. Younger patients (1530 years) were
more likely to have isoniazid-resistant TB than middle-
aged (3149 years) patients [14/62 patients (22.6%) vs.





Male gender 236 152 (64.4)
Median age (years) 196 38 (range 1763)
Geographic origin 236
Phnom Penh 125 (53.0)
Outside Phnom Penh 80 (33.9)
Unknown 31 (13.1)


















Private patient 5 (2.1)
Other NGO 1 (0.3)
Median CD4 count at TB
diagnosis (/mm3)
160 52 (range 1703)
On ART at time of TB
diagnosis
164 101 (61.6)
TB diagnosed within 60
days after starting ART
101 49 (48.5)
Started ART after TB
diagnosis
164 63 (38.4)
Started ART within 2
months after TB treatment
63 43 (68.3)
Opportunistic infection (not
TB) at TB diagnosis
196 24 (12.2)




Extra-pulmonary TB (EPTB) 236 28 (11.9)
Lymph nodes 28 12 (42.9)
Meningitis 28 8 (28.6)
Pleural 28 2 (7.1)
aFor whom data were available  not all data were available for all
patients. KSF Hospital: Khmer Soviet Friendship Hospital; ART:
antiretroviral therapy; TB: tuberculosis. Four patients had TB at
an unknown site.
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7/117 patients (6.0%); p0.003] andwere less likely to have
fully susceptible or streptomycin mono-resistant TB [40/62
patients (64.5%) vs. 95/117 patients (81.2%); p0.018];
otherwise there was no association between age and drug
resistance. Similarly, there were no statistically significant
differences in TB drug resistance between patients from
Phnom Penh and patients from elsewhere, and those with
different CD4 count levels. MDR TB occurred more in
patients with HIV diagnosed over a year prior to the TB
diagnosis (11/58, 19%) than those with a more recent
Table 3. M. tuberculosis resistance in 236 HIV-infected patients
Resistance pattern
Case definition Fully susceptible MDR TB R or RS resistance H or HS resistance S mono-resistance Total patients
New case 132 (70.6) 7 (3.7) 3 (1.6) 26 (13.9) 19 (10.2) 187 (100)
Previously treated case 14 (36.8) 11 (28.9) 7 (18.4) 3 (7.9) 3 (7.9) 38 (100)
Pa B0.001 B0.001 B0.001 0.43  
Other case definition 8 1 1 1 0 11 (100)
Sub-totals 154 (65.3) 19 (8.1) 11 (4.7) 30 (12.7) 22 (9.3) 236 (100)
Total 154 (65.3) 82 (34.7) 236 (100)
aThe difference between proportion of resistance in new versus previously treated cases. MDR TB: multidrug resistant TB; R or RS:
resistance to rifampicin or rifampicin and streptomycin; H or HS: resistance to isoniazid or isoniazid and streptomycin; S: streptomycin
resistance. No ethambutol resistance detected. Pyrazinamide not tested.
Table 4. Patterns of TB drug resistance in HIV patients by patient characteristics
Pattern of TB resistance
Patient characteristics Number of patientsa (%)
Fully susceptible/only
streptomycin resistant MDR R/RS H/HS
Gender 236 176 (74.6) 19 (8.1) 11 (4.7) 30 (12.7)
Male 152 115 (75.7) 13 (8.6) 6 (3.9) 18 (11.8)
Female 84 61 (72.6) 6 (7.1) 5 (6.0) 12 (14.3)
Age (years) 196 150 (76.5) 17 (8.7) 7 (3.6) 22 (11.2)
1530 62 40 (64.5)b 5 (8.1) 3 (4.8) 14 (22.6)
3149 117 95 (81.2) 11 (9.4) 4 (3.4) 7 (6.0)
]50 17 15 1 (5.9) 0 1
Place of origin 236 176 (74.6) 19 (8.1) 11 (4.7) 30 (12.7)
Phnom Penh 125 96 (76.8) 11 (8.8) 3 (2.4) 15 (12)
Outside Phnom Penh 80 58 (72.5) 7 (8.8) 6 (7.5) 9 (11.3)
Unknown 31 22 (73.3) 1 (3.2) 2 (6.5) 6 (19.4)
CD4 count at TB diagnosis (/mm3) 160 124 (77.5) 14 (8.8) 3 (1.9) 19 (11.9)
B50 76 61 (80.3) 5 (6.6) 2 (2.6) 8 (10.5)
50200 54 41 (75.9) 4 (7.4) 1 (1.9) 8 (14.8)
200 30 22 (73.3) 5 (16.7) 0 3 (10.0)
HIV duration prior to TB diagnosis 196 150 (76.5) 17 (8.7) 7 (3.6) 22 (11.4)
B1 year (or concurrent HIV diagnosis) 138 109 (79.0) 6 (4.3) 4 (2.9) 19 (13.8)
1 year prior 58 41 (70.7) 11 (19.0) 3 (5.2) 3 (5.2)
Antiretroviral therapy (ART) 164 123 (75.0) 17 (10.4) 7 (4.3) 17 (10.4)
On ART at TB diagnosis 101 68 (67.3) 15 (14.9) 7 (6.9) 11 (10.9)
TB diagnosed within 60 days after
starting ART
49 36 (73.5) 4 (8.2) 2 (4.1) 7 (14.3)
Not on ART at TB diagnosis 63 55 (87.3) 2 (3.2) 0 6 (9.5)
Started ART within 60 days after TB
treatment
43 36 (83.7) 2 (4.7) 0 5 (11.6)
aFor whom data available; not all data were available for all patients; bstatistically significant differences are highlighted in bold (see
Results).
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diagnosis of HIV infection (6/138, 4.3%; p0.0018).
Patients who were already on ART were more likely to
have MDRTB (15/101, 14.9%) than those who were not on
ART at the time of TB diagnosis (2/63, 3.2%; p0.018),
and less likely to have susceptible TB [68/101 (67.3%) vs.
55/63 (87.3%); p0.0051].
There were 284 positive specimens recorded from 236
patients. Respiratory specimens were the most common
(204/284, 72%): 189 spontaneously produced sputa, 11
gastric fluid aspirates, and 4 BAL specimens. Of the
respiratory specimens, 149 (73%) were smear-positive, 48
(24%) were smear-negative, and the smear status of seven
was unknown. Other non-respiratory specimens (67/284,
23.6%) included pus, cerebrospinal fluid, faeces, pleural
fluid, synovial fluid, blood, urine, pericardial, and
peritoneal fluid. In 13 cases (13/284, 4.6%), the specimen
type was not recorded. TB was diagnosed from culture of
67 non-respiratory specimens (67/284, 23.6%), with DR
TB being identified from culture of 27/67 non-respiratory
specimens (40.3%) and MDR TB from 7/67 (10.4%) non-
respiratory specimens (10.4%).
Discussion
This study describes resistance to first-line TB drugs in a
cohort of culture-positive TBHIV co-infected adults at a
large public hospital in Phnom Penh. We found that
34.7% of patients were infected with an M. tuberculosis
isolate exhibiting some form of drug resistance. MDR TB
was found in 8.1%; 36.8% of the MDR TB patients had
not previously received TB treatment, which implies that
MDR TB is being transmitted in this population. In
addition, 15.5% of new patients and 26.3% of previously
treated patients had rifampicin or isoniazid resistance.
These resistance patterns also require specific treatment
and confer risk for amplification of resistance if treated
with standard TB treatment.
The proportion of MDR TB in this cohort is higher
than previous surveys and WHO estimates of MDR TB in
Cambodia would suggest (2, 5). However, there are few
data on the prevalence of DR TB in the Cambodian popu-
lation. The last formal Cambodian TB drug resistance
survey was performed in 20002001 (5) and found a pre-
valence of any drug resistance of 10.1% amongst new
cases and 16.6% amongst previously treated cases. The
prevalence of HIV infection in these patients was not
known.
Little is known about the prevalence of DRTB amongst
HIV-infected patients in Cambodia. The CAMELIA
study (6) reports MDR TB in 2% and isoniazid-resistant
TB in 11% of 645 HIV-infected patients. A laboratory-
based study from Phnom Penh published in 2009 found
an MDR TB prevalence of 5.5% in 98 samples from
HIV-infected patients (7); however, clinical data and case
definitions were not available for these patients.
The comparatively high prevalence of DR TB in our
cohort (34.7%) may reflect an increasing incidence of
DR TB in Cambodian HIV-infected patients, and possibly
in the general population. However, our results, from a
specific population of patients in a tertiary hospital
(who are perhaps more complex than other patients),
may not be able to be generalised to the population as a
whole.
These data suggest the need for another formal pre-
valence study in Cambodia. Knowledge of the prevalence
of DR TB in an HIV-infected population, and the iden-
tification of DR TB in an individual HIV-infected patient,
is crucial for a number of reasons.
On an individual level, the treatment for both DR TB
(particularly MDR TB) and HIV is prolonged, expensive,
and complicated compared with the treatment for
susceptible TB and HIV co-infection. The complexities
of treatment increase the risk of patient harm (including
the risk of treatment failure) to the patient through drug
interactions, drug intolerance, and non-compliance. In
addition, treatment outcomes appear to be poorer for
HIV-infected patients who also have DR TB. Mortality
rates in MDR TB and HIV co-infected people are higher
than for HIV-infected patients with susceptible TB (12).
The co-incidence of DR TB and HIV may also have
implications for TB control programmes.
The high prevalence of DRTB in this study may indicate
that those with HIV infection are at increased risk of
acquiring DR TB. HIV infection is the primary driver in
the global spread of TB (3, 13), being the greatest risk
factor, after infection with M. tuberculosis itself, for
progression to active TB (2, 13). Although large surveil-
lance projects have been unable to support an association
between HIV infection and TB drug resistance (4, 14), data
from certain areas may suggest a link. Outbreaks of multi-
drug- and extensively-drug-resistant TB in institutions
have been associated with HIV infection in low-resource
(15) and high-resource countries (16), and in a recent
national survey involving hospitals and health centres in
Swaziland, HIV infection was independently associated
with the risk of MDR TB (17).
The rapid and accurate diagnosis of DRTB, particularly
MDR TB, is essential on both an individual and a pro-
grammatic level. Current methods of DST used in many
countries do not give useful results for many weeks. The
Cambodian National TB programme and the WHO
recommend DST for all previously treated patients with
TB; in HIV-infected TB suspects, the WHO recommends
using the XpertMTB/RIF genotypic assay (2). DST by
phenotypic methods is not widely available in labora-
tories in Cambodia, and the XpertMTB/RIF is usually
only available in a small number of private laboratories.
Laboratories with the ability to do DST or molecular
testing are usually situated in major centres and are not
generally accessible to those in remote areas.
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The rapidity with which genotypic methods are able
to identify MDR TB is their major advantage, allowing
timely initiation of appropriate MDR TB treatment
(1820). Delay in appropriate TB treatment in HIV-
infected patients with DR TB has been shown to increase
the risk of death (21). In our study, one-quarter 26.3% of
the patients with MDR TB were dead by at the time, or
soon after, the results of phenotypic DST were received.
The delay in starting appropriate MDR TB treatment
probably contributed to their deaths, and can also
contribute to the on-going transmission of DR TB (20).
There are challenges in the implementation of rapid
genotypic tests in many high burden countries (22).
This study has some limitations, the most important
being the retrospective nature of the analysis. Despite
protocols for the diagnosis of TB, many patients were
started on treatment empirically, without culture confir-
mation. It is possible that the culture-positive patients
received more systematic culture investigation because
they were more complicated or unwell. This may have
falsely elevated the proportion of DR TB. However, the
large, representative cohort of HIV-infected patients from
whom this study population was drawn included a
substantial proportion of outpatients, who are generally
less complicated.
Another source of bias may be the fact that the study
occurred in a national referral hospital, where the patients
may have been more complicated because of referral
patterns. However, patients were referred from many
different sources and geographic locations. No significant
difference was found in the proportion of DR TB in
patients from Phnom Penh compared with patients from
other areas, suggesting that the study cohort was not
unduly biased by the receipt of sick and/or complicated
patients from other cohorts or hospitals.
The history of previous treatment may have been
inaccurate in some cases: 11 patients (4.7%) did not have
an assigned case definition, and it is possible that the
number of ‘new cases’ was over-estimated, as ‘new case’
may have been the default case definition when treatment
history was unclear. However, all 19 MDR TB cases were
reviewed by the authors, meaning that these case defini-
tions are correct. A system was in place to collect and
record all the results of specimens sent for TB culture
(both positive and negative), but it is also possible that
some may have been missed.
A strength of this study is the inclusion of patients with
smear-negative pulmonary and extra-pulmonary TB. Most
DR TB prevalence studies focus on the large sub-group of
smear-positive pulmonary TB, and previous studies in
Cambodia have been either laboratory-based (7), or
clinical trials not specifically designed to describe DR TB
prevalence in HIV-infected patients (6, 8). HIV-infected
people are more likely to develop smear-negative and
extra-pulmonary TB than those without HIV infection
(23), and the exclusion of these sub-groups from descrip-
tions of DR TB in HIV-infected patients is likely to lead to
an under-estimate of DR TB prevalence. In addition, cul-
ture, and thus confirmation, of DR TB in HIV-infected
patients with smear-negative pulmonary TB and extra-
pulmonary TB is difficult in many clinical settings, leading
to further under-estimates. In this cohort of HIV-infected
patients, TB was confirmed by culture of extra-pulmonary
specimens in 23.6%; in addition, 40.3% of those non-
respiratory specimens identified DRTB. This demonstrates
that analysis of extra-pulmonary specimens is feasible, and
necessary, in the diagnosis and appropriate management of
TB and DR TB in resource-limited settings. The inclusion
of all sites of TB infection in our study allows us to provide
a general picture of TBHIV co-infection.
Conclusions
There is a paucity of data on TB drug resistance in
Cambodia, particularly amongst HIV-infected patients.
Our data show a high proportion of drug resistance
amongst new and previously treated patients with TB
HIV co-infection in a referral hospital in Phnom Penh.
This has implications for treatment on an individual level,
and for the detection and control of TB on a population
level, for which additional surveillance studies are re-
quired. In particular, these data reinforce the urgent need
for accessible means of rapidly identifying and treating
drug-resistant TB for high-burden and resource-limited
countries.
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